| Name | Title | Contact Details |
|---|
INFINIDAT was founded in 2011 by industry veterans focused on solving the problems storage buyers face when they are forced to choose between cost, capacity, functionality, reliability and performance. INFINIDAT enables you to have it all – today, and at a price you can afford. Businesses depend on data and rapid access to it, and the availability of that data is critical. With the growth of digitized data outpacing the growth of storage capacity, the market for storage has grown rapidly. Yet cost and complexity are forcing buyers to constantly make trade-offs. To solve this problem and capitalize on the exploding storage market, INFINIDAT has brought to market InfiniBox™, a new generation of highly reliable, scalable, and efficient storage systems. InfiniBox™ is installed in companies around the world supporting a wide variety of applications and use cases. INFINIDAT is headquartered in Needham, Massachusetts.
Benchmark Payment Network is a Cold Spring Harbor, NY-based company in the Business Services sector.
Gemini`s commitment to product excellence has been a core value since its founding more than 30 years ago. As seen below, Gemini provides a multitude of services designed to keep our clients at the cutting edge of the industry, compliant with all regulations and competitively priced in the market.
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.
Banner Commercial is a Dallas, TX-based company in the Business Services sector.